Flowonix Medical and Cerebral Therapeutics said today that the 1st patients were implanted with the Prometra II programmable infusion system in a clinical trial evaluating the pump in patients with refractory epilepsy. The Address trial marks the 1st time a programmable, implantable pump has been used to deliver medication, in this case valproate, directly to the brain.
The Prometra micro-infusion device controls drug delivery to a region of the brain associated with medically refractory epilepsy.
Get the full story at our sister site, Drug Delivery Business News.